ARCH VENTURE PARTNERS
ARCH VENTURE PARTNERS is a Pre-seed, Seed, Series A and Series C+ fund in the US and Global writing $500K–$5M checks into biotechnology, life-sciences, physical-sciences and DeepTech.
- Stages
- Pre-seed, Seed, Series A, Series C+
- Sectors
- biotechnology, life-sciences, physical-sciences, DeepTech
- Check size
- $500K–$5M
- Invests in
- US-wide, Global
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 1986
- Assets under management
- $10.6B
- Website
- archventure.com
Thesis
ARCH Venture Partners is a venture capital firm specializing in early-stage investments across biotechnology, life sciences, advanced materials, and physical sciences, with a focus on commercializing academic research. The firm targets transformative technologies with the potential to significantly impact human health, particularly in areas like infectious disease, mental health, immunology, and genomic tools. Operating primarily in North America with a global outlook, ARCH co-founds companies with leading scientists, taking a hands-on approach and often leading investment rounds. The firm is actively deploying capital from Fund XIII, a $3 billion fund closed in September 2024, and manages approximately $10.6 billion in assets.
Common questions
Does ARCH VENTURE PARTNERS invest at the Pre-seed stage?
Yes. ARCH VENTURE PARTNERS lists Pre-seed, Seed, Series A and Series C+ among the stages it invests in.
What check size does ARCH VENTURE PARTNERS write?
ARCH VENTURE PARTNERS writes $500K–$5M checks.
Where does ARCH VENTURE PARTNERS invest?
ARCH VENTURE PARTNERS invests in the US and Global.